More Articles

History of biosimilar monoclonal antibodies regulation in EU Biosimilars/Research | Posted 14/12/2012

Monoclonal antibodies (mAbs) are high molecular weight proteins (~150 kDa), with highly complex secondary and tertiary structures, subject to post-translational modifications, such as glycosylation.

US pharmacists positive about generic drugs Generics/Research | Posted 14/12/2012

Pharmacists, prescribers and patients often voice concerns about the safety and efficacy of generic drugs when they are substituted for brand-name drugs. Results of a survey, reported by Ms Laurie...

EU health spending in 2010 decreases for first time since 1975 Reports | Posted 14/12/2012

Health spending fell across the EU in 2010, governments affected by continuing austerity measures tried to save money by reducing spending on health, according to Health at a Glance: Europe 2012, a...

Teva cost-cutting and re-organization Pharma News | Posted 14/12/2012

Teva Pharmaceutical Industries’ (Teva’s) new Chief Executive vowed to reshape the drugmaker and reduce annual costs by up to US$2 billion over the next five years, making it into ‘the most indispen...

Safety and efficacy of generic tenofir/lamivudine/efavirenz combination Generics/Research | Posted 14/12/2012

New research shows the safety and efficacy of a generics combination of tenofir, lamivudine and efavirenz in the treatment of HIV-infected patients in Thailand [1].

Overview of research on manufacturing statistics and innovations of biosimilars in 2012 Biosimilars/Research | Posted 14/12/2012

Period: January to August 2012 Manufacturing of biosimilars is much more challenging than producing traditional small molecule generics. Reasons for this include, in the first place, the huge...

India’s patent office at odds with Big Pharma Policies & Legislation | Posted 14/12/2012

India and its patent laws are increasingly being challenged by Big Pharma. In its most recent decision, the Indian Patent Office has rejected AstraZeneca’s patent appeal on Iressa (gefitinib). Some...

Overview of research on ‘specific’ policies aimed at generics in 2012 Generics/Research | Posted 14/12/2012

Period: January to August 2012 Countries around the world have embraced generics due to their cost-saving potential. Many governments already have policies in place to promote the use of gener...